The issue of treatment regret comes up regularly among men after first-line treatment for localized prostate cancer, but has been less commonly addressed among men with recurrent disease post-treatment. Mahal et al. used data from the prospective Comprehensive, Observational, Multicenter, Prostate Adenocarcinoma (COMPARE) registry to study treatment regret among men with biochemically recurrent prostate cancer […]![]()
